Should We Bury HbA1c?

Laura B Bodding,Irl B Hirsch

DOI: https://doi.org/10.1089/dia.2024.0028

2024-02-14

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism

What problem does this paper attempt to address?

Recent Improvements in Attainment of the Hemoglobin A1c Target of ≤7.0% among Adults with Type 1 Diabetes in Ontario: A Retrospective Cohort Study

Alanna Weisman,Gillian L. Booth,Karl Everett,George A Tomlinson,Gillian Booth

DOI: https://doi.org/10.1089/dia.2024.0017

2024-03-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Estimated Cost of Injectable Medication Waste Attributable to Syringe Dead Space.

S. Blalock,W. Zule,Ashley L Cole,Matthew S Dixon,L. Dunlap,G. Zarkin,C. Oramasionwu

DOI: https://doi.org/10.1001/jamainternmed.2016.2301

2016-07-01

JAMA Internal Medicine

Abstract:the simplified regimen was that many patients were able to adjust the dose of glargine when glucose levels changed with other health issues during the no-contact period. Another important finding of the study is that the level of HbA1c did not correlate with duration of hypoglycemia before or after simplification of the regimen, suggesting that HbA1c level is a poor predictor of the risk of hypoglycemia. Our previous study has shown that the HbA1c levels may not correlate with estimated average glucose in older populations.7 The combination of these findings suggests that liberating the HbA1c goals in frail older patients is not adequate to protect against the risk of hypoglycemia. The type of glucose-lowering agents and the strategy for their use are important to lower the risk of hypoglycemia.

Medicine
A scalable application of Artificial Intelligence-Driven Insulin Titration Program to transform Type 2 Diabetes Management

Mark Lowe Warren,Richard M Bergenstal,Matthew R Hager,Eran Bashan,Israel Hodish

DOI: https://doi.org/10.1089/dia.2024.0041

2024-03-08

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
CGM-derived glucometrics in adults with type 1 diabetes when switching basal insulins.

Robbe De Groote,Eveline Lefever,Sara Charleer,Phebe Donné,Christophe De Block,Chantal Mathieu,Pieter Gillard

DOI: https://doi.org/10.1089/dia.2023.0616

2024-03-22

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes

Simon Bergford,Michael C. Riddell,Robin Gal,Susana R Patton,Mark A Clements,Jennifer L Sherr,Peter Calhoun

DOI: https://doi.org/10.1089/dia.2024.0061

2024-04-27

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Mitigating Severe Hypoglycemia in Users of Advanced Diabetes Technologies: Impaired Awareness of Hypoglycemia and Unhelpful Hypoglycemia Beliefs as Targets for Interventions

Yu Kuei Lin,Wen Ye,Helen Rogers,Augustin Brooks,Elena Toschi,Dulmini Kariyawasam,Simon Heller,Nicole de Zoysa,Stephanie Amiel

DOI: https://doi.org/10.1089/dia.2024.0039

2024-04-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes.

Kathy Zhou,Steven James,Michele Gaca,Ashani Lecamwasam,Muamer Dervisevic,David N O'Neal,Nicolas Voelcker,Elif Ilhan Ekinci

DOI: https://doi.org/10.1089/dia.2024.0250

2024-07-27

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Continuous glucose monitoring metrics and hemoglobin A1c relationship in patients with type 2 diabetes treated by hemodialysis

Rodolfo Galindo,Bobak Moazzami,Katherine R. Tuttle,Richard M Bergenstal,Limin Peng,Guillermo Umpierrez

DOI: https://doi.org/10.1089/dia.2024.0145

2024-05-29

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Biological variability of glycated hemoglobin

Federica Braga,Alberto Dolci,Andrea Mosca,Mauro Panteghini

DOI: https://doi.org/10.1016/j.cca.2010.07.030

IF: 6.314

2010-11-01

Clinica Chimica Acta

Abstract:BACKGROUND: The measurement of glycated hemoglobin (HbA(1c)) has a pivotal role in monitoring glycemic state in diabetic patients. Furthermore, the American Diabetes Association has recently recommended the use of HbA(1c) for diabetes diagnosis, but a clear definition of the clinically allowable measurement error is still lacking. Information on biological variability of the analyte can be used to achieve this goal.METHODS: We systematically reviewed the published studies on the biological variation of HbA(1c) to check consistency of available data in order to accurately define analytical goals.RESULTS: The nine recruited studies were limited by choice of analytic methodology, population selection, protocol application and statistical analyses.CONCLUSIONS: There is an urgent need to determine biological variability of HbA(1c) using a specific and traceable assay, appropriate protocol and appropriate statistical evaluation of data.

medical laboratory technology
Compound Heterozygous with Hb G-Taipei and Hb Lepore-Boston-Washington: an Unexpected Finding Triggered by HbA1c Measurement

Yu Li,Anping Xu,Juan He,Limin Huang,Li Lin,Jie Li,Yong Xia,Ling Ji

DOI: https://doi.org/10.1016/j.plabm.2024.e00379

2024-01-01

Practical Laboratory Medicine

Abstract:BackgroundHemoglobin A1c has been widely used to diagnose and monitor diabetes. However, the accuracy of HbA1c analysis can be significantly affected by hemoglobin variants, leading to falsely low or elevated levels and misdiagnosis or inappropriate diabetes management.Case reportIn this study, we present the case of a 23-year-old man with undetectable HbA1c levels during his annual checkup by high-performance liquid chromatography (HPLC) and capillary electrophoresis (CE). To investigate the reason for HbA1c absence, Sanger sequencing, multiplex ligation-dependent probe amplification assay (MLPA), long-read single molecule real-time sequencing (SMRT) and MALDI-TOF mass spectrometry (MS) were performed, and the proband was identified as compound heterozygous of β-thalassemia with Hb G-Taipei (HBB:c.68A > G) and Hb Lepore-Boston-Washington (NG_000007.3:g.63632_71046del).ConclusionThe combination of these molecular technologies including MLPA, long-read SMRT sequencing and MALDI-TOF MS is beneficial for identifying rare hemoglobin variants. This case also provides essential evidence for uncovering the effect of compound heterozygosity for Hb Lepore-Boston-Washington and Hb G-Taipei on hematological phenotypes and HbA1c analysis.
Erratum. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care 2021;44:390–398

Anita Jeyam,Helen Colhoun,Stuart McGurnaghan,Luke Blackbourn,Timothy J. McDonald,Colin N.A. Palmer,John A. McKnight,Mark W.J. Strachan,Alan W. Patrick,John Chalmers,Robert S. Lindsay,John R. Petrie,Sandeep Thekkepat,Andrew Collier,Sandra MacRury,Paul M. McKeigue

DOI: https://doi.org/10.2337/dc21-er04b

2021-03-17

Diabetes Care

Abstract:The authors report that the following errors occurred in transcribing the results of the statistical computations into the abstract and text. In the , "insulin dose at baseline, 27% lower (P = 2 × 10−39)" should be "insulin dose at baseline, 9% lower (P = 2 × 10−17)." In the Results, under the section C-Peptide Association with Insulin Dose, "(ratio of geometric means 0.91, P = 2 × 10−39)" should be "(ratio of geometric means 0.91, P = 2 × 10−17)."

endocrinology & metabolism
Erratum. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770–781

Stephen I. Stone,Ashok Balasubramanyam,Jennifer E. Posey

DOI: https://doi.org/10.2337/dc24-er09a

2024-06-11

Diabetes Care

Abstract:On p. 777 of the article cited above, it was incorrectly stated that patients with pancreatic diabetes may have elevated fecal elastase. The correct text is as follows: “In the case of pancreatic diabetes, patients may have low fecal elastase.” The authors apologize for the error. The online version of the article (https://doi.org/10.2337/dci23-0038) has been revised.

endocrinology & metabolism
Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276-1298

Moshe Phillip,Peter Achenbach,Ananta Addala,Anastasia Albanese-O'Neill,Tadej Battelino,Kirstine J Bell,Rachel E J Besser,Ezio Bonifacio,Helen M Colhoun,Jennifer J Couper,Maria E Craig,Thomas Danne,Carine de Beaufort,Klemen Dovc,Kimberly A Driscoll,Sanjoy Dutta,Osagie Ebekozien,Helena Elding Larsson,Daniel J Feiten,Brigitte I Frohnert,Robert A Gabbay,Mary P Gallagher,Carla J Greenbaum,Kurt J Griffin,William Hagopian,Michael J Haller,Christel Hendrieckx,Emile Hendriks,Richard I G Holt,Lucille Hughes,Heba M Ismail,Laura M Jacobsen,Suzanne B Johnson,Leslie E Kolb,Olga Kordonouri,Karin Lange,Robert W Lash,Åke Lernmark,Ingrid Libman,Markus Lundgren,David M Maahs,M Loredana Marcovecchio,Chantal Mathieu,Kellee M Miller,Holly K O'Donnell,Tal Oron,Shivajirao P Patil,Rodica Pop-Busui,Marian J Rewers,Stephen S Rich,Desmond A Schatz,Rifka Schulman-Rosenbaum,Kimber M Simmons,Emily K Sims,Jay S Skyler,Laura B Smith,Cate Speake,Andrea K Steck,Nicholas P B Thomas,Ksenia N Tonyushkina,Riitta Veijola,John M Wentworth,Diane K Wherrett,Jamie R Wood,Anette-Gabriele Ziegler,Linda A DiMeglio

DOI: https://doi.org/10.2337/dc24-er11a

2024-09-06

Diabetes Care

Abstract:In the article cited above, incorrect affiliation information was given for author Linda A. DiMeglio. The correct affiliation for Linda A. DiMeglio is Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN. The online version of the article (https://doi.org/10.2337/dci24-0042) has been updated to correct the error.
Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens

Eugene E. Wright,Jr.,Carol H Wysham,Richard M Bergenstal

DOI: https://doi.org/10.1089/dia.2024.0107

2024-05-18

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Glycated hemoglobin (HbA1c): old dogmas, a new perspective?

Giuseppe Lippi,Giovanni Targher

DOI: https://doi.org/10.1515/cclm.2010.144

2010-01-01

Abstract:The hemoglobin A1c (HbA1c) assay provides a reliable measure of chronic glycemia and correlates well with the risk of long-term diabetes complications, so that it is currently considered the test of choice for monitoring and chronic management of diabetes. Recently, HbA1c testing has been included within the diagnostic criteria recommended for diagnosis of diabetes in nonpregnant individuals by the American Diabetes Association (ADA). The emerging concept that HbA1c can be used rather than blood glucose in the diagnosis of diabetes is highly appealing for a variety of reasons, including less sensitivity to preanalytical variables, lower within subject biological variability, little to null interference from diurnal variations, acute stress and common drugs which are known to influence glucose metabolism, as well as the fact that one single measurement might provide information for both diagnosing diabetes and tracking glycemic control. On the other hand, the use of HbA1c for screening and diagnosing diabetes also carries some limitations, including the worse diagnostic performance in different populations (i.e., pregnancy, elderly and non-Hispanic blacks), the risk of overdiagnosis in subjects with iron deficiency anemia, in subjects genetically predisposed to hyperglycation, and in those with increased red blood cell turnover. There is also a higher risk of misdiagnosis in patients with end-stage renal disease and heavy alcohol consumption. Finally, HbA1c testing might be biased due to the interference from several hemoglobin variants, is characterized by a higher imprecision than blood glucose measurement, and is more expensive. This paper will critically summarize the potential advantages and limitations of HbA1c as a recommended test for diagnosing diabetes.

medical laboratory technology
Adaptive bio-behavioral control: A pilot analysis of human-machine co-adaptation in type 1 diabetes

Patricio Colmegna,Ryan McFadden,Chiara Fabris,Benjamin Lobo,Ralf Nass,Mary Clancy-Oliveri,Sue A Brown,Boris P Kovatchev

DOI: https://doi.org/10.1089/dia.2023.0399

2024-04-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276–1298

Moshe Phillip,Peter Achenbach,Ananta Addala,Anastasia Albanese-O’Neill,Tadej Battelino,Kirstine J. Bell,Rachel E.J. Besser,Ezio Bonifacio,Helen M. Colhoun,Jennifer J. Couper,Maria E. Craig,Thomas Danne,Carine de Beaufort,Klemen Dovc,Kimberly A. Driscoll,Sanjoy Dutta,Osagie Ebekozien,Helena Elding Larsson,Daniel J. Feiten,Brigitte I. Frohnert,Robert A. Gabbay,Mary P. Gallagher,Carla J. Greenbaum,Kurt J. Griffin,William Hagopian,Michael J. Haller,Christel Hendrieckx,Emile Hendriks,Richard I.G. Holt,Lucille Hughes,Heba M. Ismail,Laura M. Jacobsen,Suzanne B. Johnson,Leslie E. Kolb,Olga Kordonouri,Karin Lange,Robert W. Lash,Åke Lernmark,Ingrid Libman,Markus Lundgren,David M. Maahs,M. Loredana Marcovecchio,Chantal Mathieu,Kellee M. Miller,Holly K. O’Donnell,Tal Oron,Shivajirao P. Patil,Rodica Pop-Busui,Marian J. Rewers,Stephen S. Rich,Desmond A. Schatz,Rifka Schulman-Rosenbaum,Kimber M. Simmons,Emily K. Sims,Jay S. Skyler,Laura B. Smith,Cate Speake,Andrea K. Steck,Nicholas P.B. Thomas,Ksenia N. Tonyushkina,Riitta Veijola,John M. Wentworth,Diane K. Wherrett,Jamie R. Wood,Anette-Gabriele Ziegler,Linda A. DiMeglio

DOI: https://doi.org/10.2337/dc24-er11a

2024-09-06

Diabetes Care

Abstract:In the article cited above, incorrect affiliation information was given for author Linda A. DiMeglio. The correct affiliation for Linda A. DiMeglio is Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN. The online version of the article (https://doi.org/10.2337/dci24-0042) has been updated to correct the error.

endocrinology & metabolism
The Potential Impact of CGM Use on Diabetes-Related Attitudes and Behaviors in Adults with T2D: A Qualitative Investigation of the Patient Experience

Taylor Clark,William Polonsky,Emily Soriano

DOI: https://doi.org/10.1089/dia.2023.0612

2024-03-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Contemporary management of obesity: A comparison of bariatric metabolic surgery and novel incretin mimetic drugs

Abhayjit Singh,Steven E Nissen

DOI: https://doi.org/10.1089/dia.2024.0122

2024-04-27

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Case report: Effect of Hb E heterozygosity on HbA1c value by the Tosoh HLC-723G11

Wei Gao,Wenyu Li,Qian Zheng,Nenggang Jiang,Huairong Tang

DOI: https://doi.org/10.3389/fpubh.2023.1217662

IF: 5.2

2023-08-04

Frontiers in Public Health

Abstract:Objective: We report the effect of Hb E heterozygosity on HbA1c value by the Tosoh HLC-723G11. Case report: A 45 years-old Chinese woman presented with an abnormally low HbA1c level of 3.7% (3.9%–6.1%) in a health examination. Fasting blood glucose was normal. Blood routine examination and serum bilirubin were in the normal range. HbA1c was determined by Tosoh HLC-723G11. There was an abnormal peak between A1c and A0 on the chromatogram. Hemoglobin electrophoresis indicated that the Hb E zone accounted for 25.1%. The β-thalassemia-related genes (mutant type) were βE M/N, and the related gene CD26 (A > G) was mutated. OGTT indicated prediabetes. Conclusion: Hb E heterozygosity may reduce HbA1c value with abnormal chromatograms, as determined by a Tosoh HLC G11 analyzer. The Tosoh HLC G11 analyzer can well identify Hb E variation. In this case, further blood glucose-related tests should be performed to avoid missed diagnoses. However, a large sample size is needed to confirm this conclusion.

public, environmental & occupational health

Should We Bury HbA1c?

Recent Improvements in Attainment of the Hemoglobin A1c Target of ≤7.0% among Adults with Type 1 Diabetes in Ontario: A Retrospective Cohort Study

Estimated Cost of Injectable Medication Waste Attributable to Syringe Dead Space.

A scalable application of Artificial Intelligence-Driven Insulin Titration Program to transform Type 2 Diabetes Management

CGM-derived glucometrics in adults with type 1 diabetes when switching basal insulins.

Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes

Mitigating Severe Hypoglycemia in Users of Advanced Diabetes Technologies: Impaired Awareness of Hypoglycemia and Unhelpful Hypoglycemia Beliefs as Targets for Interventions

Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes.

Continuous glucose monitoring metrics and hemoglobin A1c relationship in patients with type 2 diabetes treated by hemodialysis

Biological variability of glycated hemoglobin

Compound Heterozygous with Hb G-Taipei and Hb Lepore-Boston-Washington: an Unexpected Finding Triggered by HbA1c Measurement

Erratum. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care 2021;44:390–398

Erratum. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770–781

Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276-1298

Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens

Glycated hemoglobin (HbA1c): old dogmas, a new perspective?

Adaptive bio-behavioral control: A pilot analysis of human-machine co-adaptation in type 1 diabetes

Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276–1298

The Potential Impact of CGM Use on Diabetes-Related Attitudes and Behaviors in Adults with T2D: A Qualitative Investigation of the Patient Experience

Contemporary management of obesity: A comparison of bariatric metabolic surgery and novel incretin mimetic drugs

Case report: Effect of Hb E heterozygosity on HbA1c value by the Tosoh HLC-723G11